FDA — authorised 3 August 1973
- Marketing authorisation holder: BRISTOL MYERS
- Status: approved
🇺🇸 Questran Light in United States
FDA authorised Questran Light on 3 August 1973
Marketing authorisations
FDA — authorised 15 August 1996
- Application: ANDA074562
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: LOCHOLEST LIGHT
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 15 August 1996
- Application: ANDA074557
- Marketing authorisation holder: EPIC PHARMA LLC
- Local brand name: CHOLESTYRAMINE
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 15 August 1996
- Application: ANDA074558
- Marketing authorisation holder: EPIC PHARMA LLC
- Local brand name: CHOLESTYRAMINE LIGHT
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 15 August 1996
- Application: ANDA074561
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: LOCHOLEST
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 2 October 1996
- Application: ANDA074554
- Marketing authorisation holder: ANI PHARMS
- Local brand name: CHOLESTYRAMINE
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 28 May 1998
- Application: ANDA074347
- Marketing authorisation holder: TEVA
- Local brand name: CHOLESTYRAMINE
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 28 May 1998
- Application: ANDA074348
- Marketing authorisation holder: TEVA
- Local brand name: CHOLESTYRAMINE LIGHT
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 30 September 1998
- Application: ANDA074555
- Marketing authorisation holder: TEVA PHARMS
- Local brand name: CHOLESTYRAMINE LIGHT
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 26 August 2005
- Application: ANDA077204
- Marketing authorisation holder: PH HEALTH
- Local brand name: CHOLESTYRAMINE
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 26 August 2005
- Application: ANDA077203
- Marketing authorisation holder: PH HEALTH
- Local brand name: CHOLESTYRAMINE LIGHT
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 25 April 2017
- Application: ANDA202902
- Marketing authorisation holder: ZYDUS PHARMS
- Local brand name: CHOLESTYRAMINE LIGHT
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 2 July 2018
- Application: ANDA202901
- Marketing authorisation holder: ZYDUS PHARMS
- Local brand name: CHOLESTYRAMINE
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 6 April 2020
- Application: ANDA211119
- Marketing authorisation holder: AJANTA PHARMA LTD
- Local brand name: CHOLESTYRAMINE
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 19 October 2021
- Application: ANDA211856
- Marketing authorisation holder: ALKEM LABS LTD
- Local brand name: CHOLESTYRAMINE
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 19 October 2021
- Application: ANDA211799
- Marketing authorisation holder: ALKEM LABS LTD
- Local brand name: CHOLESTYRAMINE LIGHT
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 21 January 2022
- Application: ANDA214877
- Marketing authorisation holder: AIPING PHARM INC
- Local brand name: CHOLESTYRAMINE
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 31 October 2024
- Application: ANDA209109
- Marketing authorisation holder: MACLEODS PHARMS LTD
- Local brand name: CHOLESTYRAMINE LIGHT
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 21 November 2024
- Application: ANDA207294
- Marketing authorisation holder: MACLEODS PHARMS LTD
- Local brand name: CHOLESTYRAMINE
- Indication: POWDER — ORAL
- Status: approved
FDA — authorised 5 March 2026
- Application: ANDA219318
- Marketing authorisation holder: MICRO LABS
- Local brand name: CHOLESTYRAMINE
- Indication: POWDER — ORAL
- Status: approved
The FDA approved the new drug application (ANDA219318) for Questran Light, a powder form of cholestyramine, on 5 March 2026. This approval allows Micro Labs to market the product in the United States. The product is indicated for oral use.
FDA
- Application: ANDA071739
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: CHOLYBAR
- Indication: BAR, CHEWABLE — ORAL
- Status: approved
Questran Light in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Questran Light approved in United States?
Yes. FDA authorised it on 3 August 1973; FDA authorised it on 15 August 1996; FDA authorised it on 15 August 1996.
Who is the marketing authorisation holder for Questran Light in United States?
BRISTOL MYERS holds the US marketing authorisation.